Clinical Trial to Assess the Efficacy of Tranexamic Acid in Reducing Blood Loss in Hip Fracture Patients.
Status:
Not yet recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
Hip fracture in elderly patients is a pathology with a high economic and health impact on the
patient himself and on the National Health System, especially considering the significant
aging of the population of the Basque Country. Despite advances, hip fracture remains in the
clinical groups with the highest in-hospital mortality. Hip fracture is associated with
numerous adverse events and high mortality.
Numerous antifibrinolytics, such as tranexamic acid (TXA), have been used to limit bleeding
in orthopedic surgery and thus prevent the need for blood transfusion. Numerous studies have
shown that the use of tranexamic acid does not increase the risk of thrombosis.
It is proposed to carry out clinical research with drugs without commercial interest. A
randomized, double-blind clinical trial to assess the efficacy of tranexamic acid in reducing
blood loss in elderly patients with hip fracture.